Passion for People Development
Antimicrobial resistance therapeutics · Basel
First-in-class antibiotics and antifungals with selective modes of action.
Three preclinical programs targeting WHO priority pathogens in patients whose immune system cannot fight infection alone - cancer, transplant, chronic illness, intensive care.
why now?
A silent pandemic is emerging
Over 750,000 bacterial and 1 million fungal infections per year in the US and Europe alone resist available therapies. Existing drugs are failing. Drug candidates with new mechanisms of action are urgently needed.
10 Million
projected annual AMR deaths by 2050
Source: O'Neill Review; WHO
1 in 8
deaths today linked to a resistant infection
Source: WHO
The most vulnerable patients include: cancer patients on chemotherapy, transplant recipients, people with chronic illness or in intensive care. Their treatments depend on antibiotics that still work. Selmod develops the ones that will.
Copyright© 2026 Selmod GmbH
All Rights Reserved.
